Genapsys
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Convertible | |
N/A | $32.5m | Series C | |
$90.0m | Series C | ||
* | $75.0m Valuation: $450m | Late VC | |
$70.0m Valuation: $450m | Series D | ||
Total Funding | €285m |
Related Content
Recent News about Genapsys
EditGenapSys operates in the biotechnology sector, specializing in DNA sequencing technology. The company has developed a novel electrical-based platform that enables accurate, scalable, and affordable sequencing. This technology is particularly useful for applications such as targeted sequencing to identify both germline and somatic mutations, as well as sequencing small genomes. GenapSys serves a diverse range of clients, including research institutions, healthcare providers, and pharmaceutical companies. The company operates in the global market, with recent expansions into Asia. GenapSys generates revenue through the sale of its sequencing platforms and related consumables. The business model is centered around providing high-accuracy sequencing solutions that are both cost-effective and scalable, making advanced DNA sequencing accessible to a broader audience.
Keywords: DNA sequencing, biotechnology, electrical detection, scalable, affordable, germline mutations, somatic mutations, small genomes, healthcare, research.